Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U04 Substudy 04A in PD-1/L1–refractory metastatic urothelial carcinoma
2023-506384-34-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label trial of pembrolizumab, zilovertamab vedotin and MK-3120 in transitional cell carcinoma (TCC) (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants who experienced at least one adverse event, Percentage of participants who discontinued study treatment due to an adverse event and 2 more. Planned start Jun 2024; status: authorised.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-506384-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506384-34-00.